Business Description
Cyclacel Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US23254L2079
Share Class Description:
CYCCP.PFD: 6% Convertible Exchangeable Preferred StockDescription
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company which develops targeted medicines for cancer and other proliferative diseases. It develops several families of anticancer drugs that act on the cell cycle, including nucleoside analogs, CDK (cyclin dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib, Sapacitabine, and plogosertib.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 114.31 | |||||
| Equity-to-Asset | 0.34 | |||||
| Debt-to-Equity | 0.01 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -54.42 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 40.8 | |||||
| 3-Year EPS without NRI Growth Rate | 42.2 | |||||
| 3-Year FCF Growth Rate | 45.7 | |||||
| 3-Year Book Growth Rate | -51.1 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 61.27 | |||||
| 9-Day RSI | 53.11 | |||||
| 14-Day RSI | 48.58 | |||||
| 6-1 Month Momentum % | -36.19 | |||||
| 12-1 Month Momentum % | -29.93 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.36 | |||||
| Quick Ratio | 1.36 | |||||
| Cash Ratio | 0.73 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 6.59 | |||||
| Forward Dividend Yield % | 6.59 | |||||
| 5-Year Yield-on-Cost % | 6.59 | |||||
| 3-Year Average Share Buyback Ratio | -144.3 | |||||
| Shareholder Yield % | -0.22 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -7439.08 | |||||
| Net Margin % | -6350.39 | |||||
| ROE % | -164.4 | |||||
| ROA % | -112.78 | |||||
| ROIC % | -891.9 | |||||
| ROC (Joel Greenblatt) % | -17929.37 | |||||
| ROCE % | -191.53 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 9.68 | |||||
| PB Ratio | 0.88 | |||||
| EV-to-EBIT | 0.07 | |||||
| EV-to-EBITDA | 0.07 | |||||
| EV-to-Revenue | -5.4 | |||||
| EV-to-FCF | 0.12 | |||||
| Earnings Yield (Greenblatt) % | 1428.57 | |||||
| FCF Yield % | -458.13 |
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:CYCCP.PFD
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Cyclacel Pharmaceuticals Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | 0 | ||
| Beta | 0.33 | ||
| Volatility % | 78.73 | ||
| 14-Day RSI | 48.58 | ||
| 14-Day ATR ($) | 1.170455 | ||
| 20-Day SMA ($) | 8.1615 | ||
| 12-1 Month Momentum % | -29.93 | ||
| 52-Week Range ($) | 5.25 - 22.58 | ||
| Shares Outstanding (Mil) |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Cyclacel Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Cyclacel Pharmaceuticals Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Cyclacel Pharmaceuticals Inc Frequently Asked Questions
What is Cyclacel Pharmaceuticals Inc(CYCCP.PFD)'s stock price today?
The current price of CYCCP.PFD is $9.15. The 52 week high of CYCCP.PFD is $22.58 and 52 week low is $5.25.
When is next earnings date of Cyclacel Pharmaceuticals Inc(CYCCP.PFD)?
The next earnings date of Cyclacel Pharmaceuticals Inc(CYCCP.PFD) is 2024-03-28 Est..
Does Cyclacel Pharmaceuticals Inc(CYCCP.PFD) pay dividends? If so, how much?
The Dividend Yield %  of Cyclacel Pharmaceuticals Inc(CYCCP.PFD) is 6.59% (As of Today), Highest Dividend Payout Ratio of Cyclacel Pharmaceuticals Inc(CYCCP.PFD) was 0. The lowest was 0. And the median was 0. The  Forward Dividend Yield % of Cyclacel Pharmaceuticals Inc(CYCCP.PFD) is 6.59%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers